ArticleExpert review of ophthalmology2007
Genetic markers and biomarkers for age-related macular degeneration.
Article in Expert review of ophthalmology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis.Molecular vision · 2010Pooled it
- Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response-a scoping review.BMJ open ophthalmology · 2024Article
- Fluorescence Lifetime Imaging of Human Sub-RPE Calcification In Vitro Following Chlortetracycline Infusion.International journal of molecular sciences · 2023Article
- Short exposure to photo-oxidative damage triggers molecular signals indicative of early retinal degeneration.Frontiers in immunology · 2023Article
- Genetic Aspects of Age-Related Macular Degeneration and Their Therapeutic Potential.International journal of molecular sciences · 2022Review
- Review
- Article
- rs10737680 polymorphism in complement factor H and neovascular age-related macular degeneration in Yogyakarta, Indonesia.Medical hypothesis, discovery & innovation ophthalmology journal · 2022Article
- Plasma biomarkers of the amyloid pathway are associated with geographic atrophy secondary to age-related macular degeneration.PloS one · 2020Article
- A computational study of VEGF production by patterned retinal epithelial cell colonies as a model for neovascular macular degeneration.Journal of biological engineering · 2017Article
- Contribution of the Nurses' Health Study to the Epidemiology of Cataract, Age-Related Macular Degeneration, and Glaucoma.American journal of public health · 2016Review
- Risk factors and biomarkers of age-related macular degeneration.Progress in retinal and eye research · 2016Review
- Vasoregression: A Shared Vascular Pathology Underlying Macrovascular And Microvascular Pathologies?Omics : a journal of integrative biology · 2015Review
- Mitochondrial DNA haplogroups confer differences in risk for age-related macular degeneration: a case control study.BMC medical genetics · 2013Article
- Smoking and age-related macular degeneration: review and update.Journal of ophthalmology · 2013Review
- Genetic analysis of simultaneous geographic atrophy and choroidal neovascularization.Eye (London, England) · 2012Article
- An association between environmental factors and the IVS4+44C>A polymorphism of the DMT1 gene in age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2012Article
- Persons with age-related maculopathy risk genotypes and clinically normal eyes have reduced mesopic vision.Investigative ophthalmology & visual science · 2011Article
- Association of HTRA1 promoter polymorphism with spinal disc degeneration in Japanese women.Journal of bone and mineral metabolism · 2010Article
- Three susceptible loci associated with primary open-angle glaucoma identified by genome-wide association study in a Japanese population.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Age-related macular degeneration (AMD) is the leading cause of visual impairment and blindness in the USA. Although the treatment of AMD has evolved to include laser photocoagulation, photodynamic therapy, surgical macular translocation and antiangiogenesis agents, treatment options for advanced AMD are limited. Furthermore, the dry form of AMD, albeit less devastating than the wet form, has even fewer viable treatment options. This review summarizes the various biomarkers of AMD and analyzes whether or not they may one day be exploited to determine risks of disease onset, measure progression of disease or even assess the effects of treatment of AMD. Potential biomarkers are important to identify since some might be utilized to reflect the disease state of a particular patient and to individualize therapy. Although studies have yielded promising results for nutrient and inflammatory biomarkers, these results have been inconsistent. At present, the best available markers of AMD risk are single nucleotide polymorphisms (SNPs). SNPs in complement factor H (CFH) and PLEKHA1/ARMS2/HtrA1 capture a substantial fraction of AMD risk and permit the identification of individuals at high risk of developing AMD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.